Compare · BNR vs CNC
BNR vs CNC
Side-by-side comparison of Burning Rock Biotech Limited (BNR) and Centene Corporation (CNC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNR and CNC operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.51B, about 306.1x BNR ($106.2M).
- Over the past year, BNR is up 120.5% and CNC is up 140.4% - CNC leads by 19.9 points.
- CNC has been more active in the news (8 items in the past 4 weeks vs 2 for BNR).
- CNC has more recent analyst coverage (25 ratings vs 2 for BNR).
- Company
- Burning Rock Biotech Limited
- Centene Corporation
- Price
- $10.98-5.39%
- $65.86-0.84%
- Market cap
- $106.2M
- $32.51B
- 1M return
- +57.31%
- +8.81%
- 1Y return
- +120.48%
- +140.36%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 2
- 8
- Recent ratings
- 2
- 25
Burning Rock Biotech Limited
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest BNR
- Director Han Yusheng bought $6,182,172 worth of Ordinary Shares (731,410 units at $8.45), increasing direct ownership by 4% to 18,404,086 units (SEC Form 4)
- Burning Rock Announces Founder’s Purchase of Its ADSs
- Burning Rock Reports First Quarter 2026 Financial Results
- SEC Form 6-K filed by Burning Rock Biotech Limited
- Amendment: SEC Form SCHEDULE 13G/A filed by Burning Rock Biotech Limited
- Burning Rock Publishes 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by Burning Rock Biotech Limited
- SEC Form 4 filed by Han Yusheng
- Burning Rock Announces Founder's Purchase of Its ADSs
- SEC Form 3 filed by new insider Deng Feng
Latest CNC
- Director Tyler Lauren M was granted 3,155 shares, increasing direct ownership by 5,172% to 3,216 units (SEC Form 4)
- CENTENE CORPORATION TO HOST 2026 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL
- CENTENE SUBSIDIARY MERIDIAN HEALTH PLAN OF ILLINOIS AWARDED ILLINOIS MEDICAID CONTRACT
- Director Tyler Lauren M was granted 61 shares (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 465 shares, increasing direct ownership by 2% to 25,213 units (SEC Form 4)
- Director Tanji Kenneth was granted 581 shares, increasing direct ownership by 5% to 12,490 units (SEC Form 4)
- Director Eppinger Frederick H was granted 833 shares, increasing direct ownership by 0.23% to 369,538 units (SEC Form 4)
- Director Coughlin Christopher J was granted 562 shares, increasing direct ownership by 3% to 18,711 units (SEC Form 4)
- Health Net Providing Special Assistance to Members and Providers Affected by Palos Warehouse Fire in Los Angeles
- RBC Capital Mkts initiated coverage on Centene with a new price target